资讯

Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market ...
August 20, 2024 — 01:04 pm EDT Written by Zacks Equity Research for Zacks -> Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge.
Nevro Corp. (NVRO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and ...
Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. Learn more about NVRO stock here.
Nevro Corp. (NYSE: NVRO) Q1 2024 Earnings Call Transcript May 8, 2024 Nevro Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is ...
Nevro Stock Performance Shares of NVRO stock opened at $5.85 on Monday. Nevro Corp. has a 12 month low of $3.17 and a 12 month high of $11.65. The company has a debt-to-equity ratio of 0.67, a ...
The U.S. commercial launch of Nevro's proprietary 10 kHz High Frequency SCS Therapy for PDN, post its FDA approval in late July 2021, raises optimism in the stock.
Following the acquisition of Nevro, Globus Medical projects net sales to be in the range of $2.80-$2.90 billion (up from $2.66-$2.69 billion) for 2025.
Estimate Trend Nevro witnessed a negative estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its loss per share has widened from $3.77 to $3.79.